News

Dr. Gabriel Levin, gynecologic oncologist at the McGill University Health Centre, and Director of Oncology at CureLab Oncology Inc., recently presented new clinical findings at the 27th Congress of the European Society of Gynaecological Oncology (ESGO 2026) in Copenhagen, highlighting a promising therapeutic advance for women with platinum-resistant ovarian cancer (PROC).

Base to Base biotech podcast 51: Ovarian cancer, blue crayfish, and stopping brittle bone disease

At the 2026 Congress of the European Society of Gynaecological Oncology (ESGO) in Copenhagen, Dr Gabriel Levin of the McGill University Health Centre will present Phase II data evaluating the investigational DNA therapy Elenagen in combination with gemcitabine for platinum-resistant ovarian cancer (PROC); one of the most aggressive and treatment-refractory settings in gynecologic oncology.

Alexander Shneider, founder and CEO of CureLab Oncology, Inc. shared a post on LinkedIn: “We are honored to see our recent clinical data featured in EMJ Oncology. For patients with platinum‑resistant ovarian cancer – one of the most challenging diagnoses in oncology – these findings point toward what may become a meaningful paradigm shift.

Adding therapy to chemo shown to extend survival in small cancer trial

In this episode of the Talking Biotech podcast, host Dr. Kevin Folta engages with Dr. Alex Schneider, CEO and founder of CureLab, to discuss innovative approaches to cancer treatment, particularly focusing on the challenges posed by refractory cancers such as triple-negative breast cancer and platinum-resistant ovarian cancer.

Elenagen, developed by biotech firm CureLab Oncology, is designed to modulate the immune response and target cancer-associated inflammation.

Elenagen, a novel DNA immunotherapy doubles survival time for ovarian cancer patients in breakthrough Phase II study. Elenagen, a first-in-class plasmid DNA therapy (immunotherapy), in combination with standard gemcitabine chemotherapy increased median overall survival (OS) from 13 months to over 25 months in patients with tough ovarian cancers.() The data come from findings published in the International Journal of Gynecological Cancer.

All received standard gemcitabine chemotherapy, and half also received elenagen, being developed by CureLab Oncology, as a once-weekly injection into the muscle.